Overview

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
0
Participant gender:
All
Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Atorvastatin
Atorvastatin Calcium
Simvastatin
Torcetrapib
Criteria
Inclusion Criteria:

- eligible for statin treatment for LDL cholesterol by NCEP guidelines

Exclusion Criteria:

- Women who are pregnant or lactating, or planning to become pregnant.

- Subjects taking any drugs known to be associated with an increased risk of myositis in
combination with HMG-CoA reductase inhibitors.

- Subjects with significant liver or kidney disease or significant heart failure.